|
 The trial tested two doses of the drug, PBT2, in 109
patients with Huntington's disease, which is characterized by a loss
in coordination and cognitive decline due to a degeneration of nerve
cells in certain parts of the brain.
The company said a higher dose of the drug also improved executive
function of the brain, which includes a person's ability to plan
activities.
Prana said there were no substantial differences in adverse events
in patients treated with the drug, and those on placebo.
Only one of the ten serious adverse events was related to the
treatment, the company said.
Prana said it would start a late-stage study of the drug to treat
Huntington's disease. The company is also testing the drug in a
mid-stage study for Alzheimer's disease.
The Australia-based company's shares closed at $7.25 on the Nasdaq
on Friday. (Reporting by Vrinda Manocha in
Bangalore; editing by Sriraj Kalluvila)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
